Citations (173)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Yong-Kuan Jiang, Kai-Yue Xin, Hong-Wei Ge, Fei-Juan Kong & Gang Zhao. (2019) Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice. Diabetes, Metabolic Syndrome and Obesity 12, pages 2095-2105.
Read now
Read now
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis & Vasilios G. Athyros. (2017) The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology 10:11, pages 1251-1261.
Read now
Read now
Paola Fioretto & Angelo Avogaro. (2017) Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 517-527.
Read now
Read now
Peter R. Chai, Caitlin Bonney, Eike Blohm, Edward W. Boyer & Kavita M. Babu. (2017) Canagliflozin-associated diabetic ketoacidosis: a case report. Toxicology Communications 1:1, pages 2-5.
Read now
Read now
Matthew R. Weir. (2016) The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgraduate Medicine 128:3, pages 290-298.
Read now
Read now
Maka S Hedrington & Stephen N Davis. (2015) Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:4, pages 613-623.
Read now
Read now
Michael A Nauck. (2014) Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy 8, pages 1380-1380.
Read now
Read now
Rosemarie Lajara. (2014) The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 15:17, pages 2565-2585.
Read now
Read now
Elizabeth M Lamos, Lisa M Younk & Stephen N Davis. (2014) Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opinion on Investigational Drugs 23:6, pages 875-882.
Read now
Read now
Vasileios Andrianesis & John Doupis. (2013) The role of kidney in glucose homeostasis – SGLT2 inhibitors, a new approach in diabetes treatment. Expert Review of Clinical Pharmacology 6:5, pages 519-539.
Read now
Read now
Aaishwarya B. Deshmukh, Maharshi C. Patel & Bharat Mishra. (2013) SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus. Renal Failure 35:4, pages 566-572.
Read now
Read now
Jean M Whaley, Mark Tirmenstein, Timothy P Reilly, Simon M Poucher, JoAnne Saye, Shamik Parikh & James F List. (2012) Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 5, pages 135-148.
Read now
Read now
Jan Basile. (2011) A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition. Postgraduate Medicine 123:4, pages 38-45.
Read now
Read now
Harold Bays. (2009) From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Current Medical Research and Opinion 25:3, pages 671-681.
Read now
Read now
Füsun Gültekin, Gülümser H. Erdoĝan, Uĝur Özersoy & Hakan Alagözlü. (1993) The Effects of Angiotensin-Converting Enzyme Inhibitors on the Clinical and Biochemical Parameters in Diabetic Nephropathy. Renal Failure 15:5, pages 615-622.
Read now
Read now
C. E. Mogensen. (1971) Glomerular Filtration Rate and Renal Plasma Flow in Normal and Diabetic Man during Elevation of Blood Sugar Levels. Scandinavian Journal of Clinical and Laboratory Investigation 28:2, pages 177-182.
Read now
Read now
Articles from other publishers (157)
Loubna Hamdini, Frederique Defrance, Mikael Chetboun, Julie Kerr-Conte, Marie Frimat, François Pattou, Marie-Christine Vantyghem, François Glowacki & Mehdi Maanaoui. (2023) Usage des gliflozines dans la maladie rénale chronique. La Presse Médicale Formation 4:2, pages 129-134.
Crossref
Crossref
Jothydev Kesavadev, Fatema Jawad, Asma Deeb, Ankia Coetzee, M. A. Jalil Ansari, Dina Shrestha, Noel Somasundaram & Sanjay Kalra. 2023. The Diabetes Textbook. The Diabetes Textbook
127
142
.
Michael A. Via & Jeffrey I. Mechanick. 2023. Diabetes and Cardiovascular Disease. Diabetes and Cardiovascular Disease
375
397
.
Shinsuke Noso & Hiroshi Ikegami. 2023. Biomarkers in Diabetes. Biomarkers in Diabetes
615
628
.
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki & Christos Mantzoros. (2022) Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 137, pages 155332.
Crossref
Crossref
Radica Z. Alicic, Joshua J. Neumiller, Rodolfo J. Galindo & Katherine R. Tuttle. (2022) Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney International Reports 7:12, pages 2589-2607.
Crossref
Crossref
Shivani Sharma, Amit Mittal, Shubham Kumar & Anu Mittal. (2022) Structural Perspectives and Advancement of SGLT2 Inhibitors for the
Treatment of Type 2 Diabetes. Current Diabetes Reviews 18:6.
Crossref
Crossref
Shinsuke Noso & Hiroshi Ikegami. 2022. Biomarkers in Diabetes. Biomarkers in Diabetes
1
14
.
Volker Vallon & Takahiko Nakagawa. 2011. Comprehensive Physiology. Comprehensive Physiology
2995
3044
.
Hongru Yan, Yi Wen & Bicheng Liu. (2021) Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease. Diabetic Nephropathy 1:3, pages 97-108.
Crossref
Crossref
Keisuke Monobe, Shinsuke Noso, Naru Babaya, Yoshihisa Hiromine, Yasunori Taketomo, Fumimaru Niwano, Sawa Yoshida, Sara Yasutake, Tatsuro Minohara, Yumiko Kawabata & Hiroshi Ikegami. (2020) Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus. Journal of Diabetes Investigation 12:5, pages 728-737.
Crossref
Crossref
Jacek Rysz, Beata Franczyk, Maciej Radek, Aleksandra Ciałkowska-Rysz & Anna Gluba-Brzózka. (2021) Diabetes and Cardiovascular Risk in Renal Transplant Patients. International Journal of Molecular Sciences 22:7, pages 3422.
Crossref
Crossref
Noha SAYED, Ikue MURATA, Osama ABDALLA, Omnia KILANY, Amina DESSOUKI & Kazuaki SASAKI. (2021) Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model. Journal of Veterinary Medical Science 83:10, pages 1597-1603.
Crossref
Crossref
Anirudh Manoj, Subham Das, Anu Kunnath Ramachandran, Angel T Alex & Alex Joseph. (2020) SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Medicinal Chemistry 12:21, pages 1961-1990.
Crossref
Crossref
Volker Vallon. (2020) Glucose transporters in the kidney in health and disease. Pflügers Archiv - European Journal of Physiology 472:9, pages 1345-1370.
Crossref
Crossref
Volker Vallon & Scott C. Thomson. (2020) The tubular hypothesis of nephron filtration and diabetic kidney disease. Nature Reviews Nephrology 16:6, pages 317-336.
Crossref
Crossref
Michel Marre. (2020) Carl Erik Mogensen et le concept de néphropathie diabétique débutante. Médecine des Maladies Métaboliques 14:3, pages 273-274.
Crossref
Crossref
Jennifer R. Snaith, Deborah J. Holmes-Walker & Jerry R. Greenfield. (2020) Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?. Trends in Endocrinology & Metabolism 31:2, pages 150-164.
Crossref
Crossref
Ricardo Pereira-Moreira & Elza Muscelli. (2020) Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review. Journal of Diabetes Research 2020, pages 1-17.
Crossref
Crossref
Konstantinos Imprialos, Konstantinos Stavropoulos & Vasilios Papademetriou. (2019) Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics 15:4, pages 519-530.
Crossref
Crossref
Vishnu Garla, Swetha Kanduri, Licy Yanes-Cardozo & Lillian F. Lién. (2019) Management of diabetes mellitus in chronic kidney disease. Minerva Endocrinologica 44:3.
Crossref
Crossref
Eugenio Cersosimo & John M. Miles. (2019) Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors. Current Diabetes Reviews 15:4, pages 314-327.
Crossref
Crossref
Emily Brown, John P.H. Wilding, Thomas M. Barber, Uazman Alam & Daniel J. Cuthbertson. (2019) Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obesity Reviews 20:6, pages 816-828.
Crossref
Crossref
L. A. Wright & I. B. Hirsch. (2019) Non‐insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions. Diabetic Medicine 36:6, pages 665-678.
Crossref
Crossref
Emily Brown, Surya P. Rajeev, Daniel J. Cuthbertson & John P. H. Wilding. (2019) A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors. Diabetes, Obesity and Metabolism 21:S2, pages 9-18.
Crossref
Crossref
A. Yu. Zharikov, B. A. Balandovich, R. O. Shchekochikhina & G. V. Zharikova. (2019) KIDNEY FUNCTION IN EXPERIMENTAL DIABETES. Nephrology (Saint-Petersburg) 23:1, pages 79-83.
Crossref
Crossref
Wesley Nuffer, Briana Williams & Jennifer M. Trujillo. (2019) A review of sotagliflozin for use in type 1 diabetes. Therapeutic Advances in Endocrinology and Metabolism 10, pages 204201881989052.
Crossref
Crossref
Cheng Hu & Weiping Jia. (2019) Therapeutic medications against diabetes: What we have and what we expect. Advanced Drug Delivery Reviews 139, pages 3-15.
Crossref
Crossref
. 2019. Diabetologie. Diabetologie
13
35
.
Jothydev Kesavadev, Fatema Jawad, Asma Deeb, Ankia Coetzee, M. A. Jalil Ansari, Dina Shrestha, Noel Somasundaram & Sanjay Kalra. 2019. The Diabetes Textbook. The Diabetes Textbook
101
116
.
Shuai Li, Nan Wang, Xiaochen Guo, Junyan Li, Teng Zhang, Guiping Ren & Deshan Li. (2018) Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption. Biomedicine & Pharmacotherapy 108, pages 355-366.
Crossref
Crossref
Natalia de Albuquerque Rocha, Ian J Neeland, Peter A McCullough, Robert D Toto & Darren K McGuire. (2018) Effects of sodium glucose co-transporter 2 inhibitors on the kidney. Diabetes and Vascular Disease Research 15:5, pages 375-386.
Crossref
Crossref
Jagriti Upadhyay, Stergios A. Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A. Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis & Christos S. Mantzoros. (2018) Pharmacotherapy of type 2 diabetes: An update. Metabolism 78, pages 13-42.
Crossref
Crossref
Elia Escasany, Adriana Izquierdo-Lahuerta & Gema Medina-Gómez. 2018. Obesity. Obesity
135
162
.
Ralph A. DeFronzo. 2018. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
181
253
.
Ralph A. DeFronzo. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
74
.
Leszek Szablewski. (2017) Distribution of glucose transporters in renal diseases. Journal of Biomedical Science 24:1.
Crossref
Crossref
Mazen Alsahli & John E. Gerich. (2017) Renal glucose metabolism in normal physiological conditions and in diabetes. Diabetes Research and Clinical Practice 133, pages 1-9.
Crossref
Crossref
Oren Steen & Ronald M. Goldenberg. (2017) The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. Canadian Journal of Diabetes 41:5, pages 517-523.
Crossref
Crossref
Natalia G. Vallianou, Eleni Geladari & Christos E. Kazazis. (2017) SGLT-2 inhibitors: Their pleiotropic properties. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11:4, pages 311-315.
Crossref
Crossref
Luke Norton, Christopher E. Shannon, Marcel Fourcaudot, Cheng Hu, Niansong Wang, Wei Ren, Jun Song, Muhammad Abdul‐Ghani, Ralph A. DeFronzo, Jimmy Ren & Weiping Jia. (2017)
Sodium‐glucose co‐transporter (
SGLT
) and glucose transporter (
GLUT
) expression in the kidney of type 2 diabetic subjects
. Diabetes, Obesity and Metabolism 19:9, pages 1322-1326.
Crossref
Crossref
Blythe D. Shepard & Jennifer L. Pluznick. (2017) Saving the sweetness: renal glucose handling in health and disease. American Journal of Physiology-Renal Physiology 313:1, pages F55-F61.
Crossref
Crossref
Ele Ferrannini. (2017) Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. Cell Metabolism 26:1, pages 27-38.
Crossref
Crossref
Daiji Kawanami, Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Tomoyo Akamine, Tamotsu Yokota, Kazunori Sango & Kazunori Utsunomiya. (2017) SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences 18:5, pages 1083.
Crossref
Crossref
Anton Ivanovich Korbut & Vadim Valer'evich Klimontov. (2017) Empagliflozin: a new strategy for nephroprotection in diabetes. Diabetes mellitus 20:1, pages 75-84.
Crossref
Crossref
Ashley M. Zurek, Raghunandan Yendapally & Elizabeth M. Urteaga. (2017) A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis. Diabetes Spectrum 30:2, pages 137-142.
Crossref
Crossref
Paresh Dandona & Ajay Chaudhuri. (2017) Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. International Journal of Clinical Practice 71:5, pages e12937.
Crossref
Crossref
Oren Steen & Ronald M. Goldenberg. (2017) WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. Canadian Journal of Diabetes.
Crossref
Crossref
Volker Vallon & Scott C. Thomson. (2016) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:2, pages 215-225.
Crossref
Crossref
Ralph A. DeFronzo, Luke Norton & Muhammad Abdul-Ghani. (2016) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology 13:1, pages 11-26.
Crossref
Crossref
Mazen Alsahli, Muhammad Z. Shrayyef & John E. Gerich. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
1
20
.
Mazen Alsahli, Muhammad Z. Shrayyef & John E. Gerich. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
23
42
.
Prachi Gupta, Manju Bala, Sanjeev Gupta, Anita Dua, Rajesh Dabur, Elisha Injeti & Ashwani Mittal. (2016) Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action. Pharmacological Research 113, pages 636-674.
Crossref
Crossref
Julián Segura. (2016) Abordaje de la diabetes mellitus tipo 2 a través del cotransportador sodio-glucosa tipo 2: ¿tiene sentido?. Medicina Clínica 147, pages 22-25.
Crossref
Crossref
Anne E. de Leeuw & Rudolf A. de Boer. (2016) Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects. European Heart Journal - Cardiovascular Pharmacotherapy 2:4, pages 244-255.
Crossref
Crossref
Luigi Gnudi & Janaka Karalliedde. (2016) Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. Nephrology Dialysis Transplantation 31:7, pages 1036-1043.
Crossref
Crossref
Eberhard StandlOliver SchnellDarren K. McGuire. (2016) Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. Circulation Research 118:11, pages 1830-1843.
Crossref
Crossref
S. P. Rajeev, D. J. Cuthbertson & J. P. H. Wilding. (2016) Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes, Obesity and Metabolism 18:2, pages 125-134.
Crossref
Crossref
Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux & Po Sing Leung. (2016) The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLOS ONE 11:1, pages e0147391.
Crossref
Crossref
Masanori Fukazawa, Takumi Nagata, Masayuki Suzuki, Yoshiyuki Suzuki & Yoshiki Kawabe. (2016) Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys. Folia Pharmacologica Japonica 148:5, pages 259-265.
Crossref
Crossref
James R. Bosley, Tristan S. Maurer & Cynthia J. Musante. 2016. Systems Pharmacology and Pharmacodynamics. Systems Pharmacology and Pharmacodynamics
465
507
.
Muhammad A. Abdul-Ghani, Luke Norton & Ralph A. DeFronzo. (2015) Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. American Journal of Physiology-Renal Physiology 309:11, pages F889-F900.
Crossref
Crossref
Pamela M. Katz & Lawrence A. Leiter. (2015) The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes. Canadian Journal of Diabetes 39, pages S167-S175.
Crossref
Crossref
Kentaro Yamada, Hitomi Nakayama, Satoko Yoshinobu, Seiko Kawano, Munehisa Tsuruta, Masayuki Nohara, Rika Hasuo, Shoko Akasu, Ichiro Tokubuchi, Nobuhiko Wada, Saori Hirao, Shinpei Iwata, Hiroo Kaku & Yuji Tajiri. (2015) Effects of a sodium glucose co‐transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. Journal of Diabetes Investigation 6:6, pages 699-707.
Crossref
Crossref
S. A. Brunton. (2015) The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. International Journal of Clinical Practice 69:10, pages 1071-1087.
Crossref
Crossref
Trond Jenssen & Anders Hartmann. (2015) Emerging treatments for post-transplantation diabetes mellitus. Nature Reviews Nephrology 11:8, pages 465-477.
Crossref
Crossref
Ralph A. DeFronzo. 2015. International Textbook of Diabetes Mellitus. International Textbook of Diabetes Mellitus
371
400
.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger & David Matthews. (2015) Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care 38:3, pages 403-411.
Crossref
Crossref
Robert R. Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List & Steven C. Griffen. (2015) Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Diabetes Care 38:3, pages 412-419.
Crossref
Crossref
Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Jürgen Woerle, Uli C Broedl & Odd Erik Johansen. (2015) SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research 12:2, pages 90-100.
Crossref
Crossref
Volker Vallon. (2015) The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus. Annual Review of Medicine 66:1, pages 255-270.
Crossref
Crossref
P. Darmon. (2015) Inhibiteurs de SGLT2 dans le diabète de type 1 : vraie perspective ou fausse bonne idée ?. Médecine des Maladies Métaboliques 9:1, pages S59-S63.
Crossref
Crossref
Mazen Alsahli & John E. Gerich. 2016. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
1
20
.
Yasong Lu, Steven C. Griffen, David W. Boulton & Tarek A. Leil. (2014) Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Frontiers in Pharmacology 5.
Crossref
Crossref
R.E. Gilbert. (2014) SGLT-2 inhibition in patients with kidney disease. Diabetes & Metabolism 40:6, pages S23-S27.
Crossref
Crossref
Takeshi Kadokura, Wenhui Zhang, Walter Krauwinkel, Stefanie Leeflang, James Keirns, Yuta Taniuchi, Ikumi Nakajo & Ronald Smulders. (2014) Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin. Clinical Pharmacokinetics 53:11, pages 975-988.
Crossref
Crossref
John P.H. Wilding. (2014) The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63:10, pages 1228-1237.
Crossref
Crossref
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch, Sabine Arnolds, Linda Morrow, Heike Spitzer, Keith Demarest & Paul Rothenberg. (2014) Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE 9:8, pages e105638.
Crossref
Crossref
Luca De Nicola, Francis B. Gabbai, Maria Elena Liberti, Adelia Sagliocca, Giuseppe Conte & Roberto Minutolo. (2014) Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. American Journal of Kidney Diseases 64:1, pages 16-24.
Crossref
Crossref
J.B. Jamuna & C.D. Nandini. (2014) Feeding of banana flower and pseudostem to diabetic rats results in modulation of renal GLUTs, TGFβ, PKC and extracellular matrix components. Nutrition, Metabolism and Cardiovascular Diseases 24:6, pages 623-631.
Crossref
Crossref
Farhad M. Hasan, Mazen Alsahli & John E. Gerich. (2014) SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Research and Clinical Practice 104:3, pages 297-322.
Crossref
Crossref
J. Sällström, T. Eriksson, B. B. Fredholm, A. E. G. Persson & F. Palm. (2014)
Inhibition of sodium-linked glucose reabsorption normalizes diabetes-induced glomerular hyperfiltration in conscious adenosine A
1
-receptor deficient mice
. Acta Physiologica 210:2, pages 440-445.
Crossref
Crossref
Pinchas Klein, David Polidori, Orit Twito & Anat Jaffe. (2014) Impaired decline in renal threshold for glucose during pregnancy - a possible novel mechanism for gestational diabetes mellitus. Diabetes/Metabolism Research and Reviews 30:2, pages 140-145.
Crossref
Crossref
Sang Youl Rhee. (2014) The Role of the Kidney in Glucose Metabolism. The Journal of Korean Diabetes 15:3, pages 142.
Crossref
Crossref
Chang Hee JungJung Eun JangJoong-Yeol Park. (2014) A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes & Metabolism Journal 38:4, pages 261.
Crossref
Crossref
Edward C. Chao. (2014) SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clinical Diabetes 32:1, pages 4-11.
Crossref
Crossref
Mazen Alsahli & John E. Gerich. 2014. Encyclopedia of Endocrine Diseases. Encyclopedia of Endocrine Diseases
72
86
.
Harold Bays. (2013) Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Therapy 4:2, pages 195-220.
Crossref
Crossref
Satish K. GargAaron W. MichelsViral N. Shah. (2013) Use of Non-Insulin Therapies for Type 1 Diabetes. Diabetes Technology & Therapeutics 15:11, pages 901-908.
Crossref
Crossref
Ralph A. DeFronzo, Roy Eldor & Muhammad Abdul-Ghani. (2013) Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care 36:Supplement_2, pages S127-S138.
Crossref
Crossref
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger & David Matthews. (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial. American Heart Journal 166:2, pages 217-223.e11.
Crossref
Crossref
Eiji Kurosaki & Hideaki Ogasawara. (2013) Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacology & Therapeutics 139:1, pages 51-59.
Crossref
Crossref
Sayaka Maeda, Takanori Matsui, Masayoshi Takeuchi & Sho‐ichi Yamagishi. (2013) Sodium‐glucose cotransporter 2‐mediated oxidative stress augments advanced glycation end products‐induced tubular cell apoptosis. Diabetes/Metabolism Research and Reviews 29:5, pages 406-412.
Crossref
Crossref
S. Martin. (2013) Inhibition des natriumabhängigen Glukosetransporter 2Inhibition of sodium-glucose cotransporter 2. Der Diabetologe 9:4, pages 289-295.
Crossref
Crossref
Damayanthi Devineni, Christopher R. Curtin, David Polidori, Maria J. Gutierrez, Joseph Murphy, Sarah Rusch & Paul L. Rothenberg. (2013) Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology 53:6, pages 601-610.
Crossref
Crossref
Ele Ferrannini, Stephan A. Veltkamp, Ronald A. Smulders & Takeshi Kadokura. (2013) Renal Glucose Handling. Diabetes Care 36:5, pages 1260-1265.
Crossref
Crossref
Jiwen (Jim) Liu, TaeWeon Lee & Ralph A. DeFronzo. (2012) Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?. Diabetes 61:9, pages 2199-2204.
Crossref
Crossref
Chiara Ghezzi & Ernest M. Wright. (2012)
Regulation of the human Na
+
-dependent glucose cotransporter hSGLT2
. American Journal of Physiology-Cell Physiology 303:3, pages C348-C354.
Crossref
Crossref
Ele Ferrannini & Anna Solini. (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nature Reviews Endocrinology 8:8, pages 495-502.
Crossref
Crossref
G. Luippold, T. Klein, M. Mark & R. Grempler. (2012) Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes, Obesity and Metabolism 14:7, pages 601-607.
Crossref
Crossref
D. Devineni, L. Morrow, M. Hompesch, D. Skee, A. Vandebosch, J. Murphy, K. Ways & S. Schwartz. (2012) Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes, Obesity and Metabolism 14:6, pages 539-545.
Crossref
Crossref
Sun-Young Kim & A-Ree Moon. (2012) Drug-Induced Nephrotoxicity and Its Biomarkers. Biomolecules and Therapeutics 20:3, pages 268-272.
Crossref
Crossref
Celine Foote, Vlado Perkovic & Bruce Neal. (2012) Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes and Vascular Disease Research 9:2, pages 117-123.
Crossref
Crossref
Yin Liang, Kenji Arakawa, Kiichiro Ueta, Yasuaki Matsushita, Chiaki Kuriyama, Tonya Martin, Fuyong Du, Yi Liu, June Xu, Bruce Conway, Jamie Conway, David Polidori, Kirk Ways & Keith Demarest. (2012) Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE 7:2, pages e30555.
Crossref
Crossref
Stephan Martin. (2012) Ein interessanter Ansatz für die Therapie bei Diabetes. Info Diabetologie 6:1, pages 35-39.
Crossref
Crossref
R. A. DeFronzo, J. A. Davidson & S. Del Prato. (2011) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes, Obesity and Metabolism 14:1, pages 5-14.
Crossref
Crossref
Asimina Mitrakou. (2011) Kidney: Its impact on glucose homeostasis and hormonal regulation. Diabetes Research and Clinical Practice 93, pages S66-S72.
Crossref
Crossref
ADNAN SHARIF. (2011) Current and emerging antiglycaemic pharmacological therapies: The renal perspective. Nephrology 16:5, pages 468-475.
Crossref
Crossref
Ele Ferrannini. (2011) Learning From Glycosuria. Diabetes 60:3, pages 695-696.
Crossref
Crossref
Jonatan I. BaggerFilip K. KnopAsger LundHenrik VestergaardJens J. Holst & Tina Vilsbøll. (2011) Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 96:3, pages 737-745.
Crossref
Crossref
James F. List & Jean M. Whaley. (2011) Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney International 79, pages S20-S27.
Crossref
Crossref
Joaquim Calado, René Santer & José Rueff. (2011) Effect of kidney disease on glucose handling (including genetic defects). Kidney International 79, pages S7-S13.
Crossref
Crossref
Amanda Mather & Carol Pollock. (2011) Glucose handling by the kidney. Kidney International 79, pages S1-S6.
Crossref
Crossref
Clifford J. Bailey. (2011) Renal glucose reabsorption inhibitors to treat diabetes. Trends in Pharmacological Sciences 32:2, pages 63-71.
Crossref
Crossref
S Nair, F Joseph, D Ewins, J Wilding & N Goenka. (2010) From history to reality: sodium glucose co‐transporter 2 inhibitors – a novel therapy for type 2 diabetes mellitus. Practical Diabetes International 27:7, pages 311-316.
Crossref
Crossref
E. Ferrannini. (2010) Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrology Dialysis Transplantation 25:7, pages 2041-2043.
Crossref
Crossref
Amanda Mather & Carol Pollock. (2010) Renal glucose transporters: novel targets for hyperglycemia management. Nature Reviews Nephrology 6:5, pages 307-311.
Crossref
Crossref
Ralph A. DeFronzo. (2010) Overview of Newer Agents: Where Treatment Is Going. The American Journal of Medicine 123:3, pages S38-S48.
Crossref
Crossref
J. E. Gerich. (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Medicine 27:2, pages 136-142.
Crossref
Crossref
René Santer & Joaquim Calado. (2010) Familial Renal Glucosuria and SGLT2. Clinical Journal of the American Society of Nephrology 5:1, pages 133-141.
Crossref
Crossref
Olivera Marsenic. (2009) Glucose Control by the Kidney: An Emerging Target in Diabetes. American Journal of Kidney Diseases 53:5, pages 875-883.
Crossref
Crossref
Ralph A. DeFronzo. (2009) From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 58:4, pages 773-795.
Crossref
Crossref
Muhammad A. Abdul-Ghani & Ralph A. DeFronzo. (2008) Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus. Endocrine Practice 14:6, pages 782-790.
Crossref
Crossref
Hassan Rahmoune, Paul W. Thompson, Joanna M. Ward, Chari D. Smith, Guizhu Hong & John Brown. (2005) Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non–Insulin-Dependent Diabetes. Diabetes 54:12, pages 3427-3434.
Crossref
Crossref
William F. Finn & George A. Porter. 2003. Clinical Nephrotoxins. Clinical Nephrotoxins
621
655
.
W. T. Noonan & R. O. Banks. (2008) Renal Function and Glucose Transport in Male and Female Mice with Diet‐Induced Type II Diabetes Mellitus. Proceedings of the Society for Experimental Biology and Medicine 225:3, pages 221-230.
Crossref
Crossref
W. T. Noonan & R. O. Banks. (2000) Renal Function and Glucose Transport in Male and Female Mice with Diet-Induced Type II Diabetes Mellitus. Proceedings of the Society for Experimental Biology and Medicine 225:3, pages 221-230.
Crossref
Crossref
Tania Torres Rosa & Paolo Palatini. (2000) Clinical value of microalbuminuria in hypertension. Journal of Hypertension 18:6, pages 645-654.
Crossref
Crossref
K. McKenna, D. Smith, P. Barrett, A. Glenn, C. M. Kesson, J. Connell & C. J. Thompson. (2001) Angiotensin‐converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria. Diabetic Medicine 17:3, pages 219-224.
Crossref
Crossref
Bo Feldt-Rasmussen. (2000) Postprandial hyperglycaemia: potential relationship to the development and progression of diabetic nephropathy. Diabetes, Obesity and Metabolism 2:s1, pages S13-S20.
Crossref
Crossref
C. E. Mogensen. 2000. The Kidney and Hypertension in Diabetes Mellitus. The Kidney and Hypertension in Diabetes Mellitus
655
706
.
William F. Finn & George A. Porter. 1998. Clinical Nephrotoxins. Clinical Nephrotoxins
439
463
.
Carl Erik Mogensen. (2009) Diabetic Renal Disease: The Quest for Normotension—and Beyond. Diabetic Medicine 12:9, pages 756-769.
Crossref
Crossref
F. N. Ziyadeh & S. Goldfarb. 1995. Tubulointerstitial and Cystic Disease of the Kidney. Tubulointerstitial and Cystic Disease of the Kidney
175
201
.
Judith M. Stephenson & John H. Fuller. (1994) Microalbuminuria is not rare before 5 years of IDDM. Journal of Diabetes and its Complications 8:3, pages 166-173.
Crossref
Crossref
G.F. Watts, N.A. Taub, J. Mazurkiewicz & K.M. Shaw. (1993) An examination of the covariability of subclinical albuminuria in insulin-dependent diabetes mellitus: implications for monitoring microalbuminuria. Diabetes Research and Clinical Practice 21:2-3, pages 177-185.
Crossref
Crossref
Robert L. Vernier, Michael W. Steffes, Susan Sisson-Ross & S. Michael Mauer. (1992) Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney International 41:4, pages 1070-1080.
Crossref
Crossref
Fuad N. Ziyadeh & Stanley Goldfarb. (1991) The renal tubulointerstitium in diabetes mellitus. Kidney International 39:3, pages 464-475.
Crossref
Crossref
D J F Rowe, A Dawnay & G F Watts. (2016) Microalbuminuria in Diabetes Mellitus: Review and Recommendations for the Measurement of Albumin in Urine. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 27:4, pages 297-312.
Crossref
Crossref
G.F. Watts, C. Kubal & S. Chinn. (1990) Long-term variation of urinary albumin excretion in insulin-dependent diabetes mellitus: some practical recommendations for monitoring microalbuminuria. Diabetes Research and Clinical Practice 9:2, pages 169-177.
Crossref
Crossref
Tong-Yuan Tai, Lee-Ming Chuang, Chin-Hsiao Tseng, Huey-Peir Wu, Muh-Shi Chen & Boniface J. Lin. (1990) Microalbuminuria and diabetic complications in Chinese non-insulin-dependent diabetic patients: a prospective study. Diabetes Research and Clinical Practice 9:1, pages 59-63.
Crossref
Crossref
Giovanni Maria Narelli, Mauro Cignarelli, Adriano Paternostro, Vittoria Romanazzi, Giuseppe Passavanti, Rosaria Cospite, Giovanni De Pergola, Pasquale Coratelli & Riccardo Giorgino. 1989. Drugs, Systemic Diseases, and the Kidney. Drugs, Systemic Diseases, and the Kidney
377
383
.
J. Bariéty. 1989. Diseases of the Arterial Wall. Diseases of the Arterial Wall
363
377
.
Kenneth S. Kleinman & Leon G. Fine. (2009) Prognostic implications of renal hypertrophy in diabetes mellitus. Diabetes/Metabolism Reviews 4:2, pages 179-189.
Crossref
Crossref
G. C. Viberti & J. D. Walker. (2009) Diabetic nephropathy: Etiology and prevention. Diabetes/Metabolism Reviews 4:2, pages 147-162.
Crossref
Crossref
G.C. Viberti & M.J. Wiseman. (1986) The kidney in diabetes: Significance of the early abnormalities. Clinics in Endocrinology and Metabolism 15:4, pages 753-782.
Crossref
Crossref
W. Berger, R. Flückiger, H. G. Köppe, K. T. Holmes, C. E. Mountford, E. L. Nickoloff, T. G. Payne, M. H. Schreier, I. C. P. Smith & R. M. WengerRudolf Flückiger & Willi Berger. 1986. Metabolic Control in Diabetes Mellitus Beta Adrenoceptor Blocking Drugs NMR Analysis of Cancer Cells Immunoassay in the Clinical Laboratory Cyclosporine. Metabolic Control in Diabetes Mellitus Beta Adrenoceptor Blocking Drugs NMR Analysis of Cancer Cells Immunoassay in the Clinical Laboratory Cyclosporine
1
27
.
Michael E. Blank, Folkert Bode, Edith Huland, Donald F. Diedrich & Karl Baumann. (1985) Kinetic studies of d-glucose transport in renal brush-border membrane vesicles of streptozotocin-induced diabetic rats. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 844:3, pages 314-319.
Crossref
Crossref
J. Brøchner-Mortensen, M. Støckel, P. J. Sørensen, A. H. Nielsen & J. Ditzel. (1984) Proximal glomerulo-tubular balance in patients with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 27:2, pages 189-192.
Crossref
Crossref
C. E. Mogensen, R. �sterby & H. J. G. Gundersen. (1979) Early functional and morphologic vascular renal consequences of the diabetic state. Diabetologia 17:2, pages 71-76.
Crossref
Crossref
K. Irmscher. 1977. Diabetes mellitus • B. Diabetes mellitus • B
245
361
.
F. Matzkies. (1975) Untersuchungen zur Pharmakokinetik von Kohlenhydraten als Grundlage ihrer Anwendung zur parenteralen Ernährung. Zeitschrift für Ernährungswissenschaft 14:3, pages 184-217.
Crossref
Crossref
C. E. Mogensen & M. J. F. Andersen. (1975) Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: Normalization by insulin-treatment. Diabetologia 11:3, pages 221-224.
Crossref
Crossref
F. Matzkies, H. Heid, W. Fekl & G. Berg. (1975) Wirkungen einer Kohlenhydratkombinationslösung auf den Stoffwechsel bei hochdosierter Kurzzeitinfusion. Zeitschrift für Ernährungswissenschaft 14:1, pages 53-63.
Crossref
Crossref
Sergio Marigo. (1974) La glicosuria. Acta Diabetologica Latina 11:S3, pages 1-35.
Crossref
Crossref
J. Brøchner-Mortensen. (2009) THE GLOMERULAR FILTRATION RATE DURING MODERATE HYPERGLYCEMIA IN NORMAL MAN. Acta Medica Scandinavica 194:1-6, pages 31-37.
Crossref
Crossref
Knud Lundbaek. 1972.
99
129
.